Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Tools of the Trade
  • Published:

Reference-trial-informed design to explore treatment effects in trial-underrepresented subgroups

Nature Reviews Nephrology (2024)Cite this article

Subjects

Randomized controlled trials (RCT) are often regarded as the ‘gold standard’ of clinical evidence. However, their strict eligibility criteria can impact cohort diversity and limit the inclusion of some subgroups, including patients with comorbidities, older individuals or those from minority ethnic groups. Observational data, including data from electronic health records, can be used to bridge the gap in evidence but are subject to bias and confounding owing to the lack of randomization.

The ‘target trial’ emulation framework, which emulates the design of a hypothetical ‘target trial’ using observational data, has increasingly been used for causal inference1,2. Despite this approach implementing design decisions to limit the effects of bias and confounding, uncertainty remains as to whether the observed result aligns with those which would have been obtained in RCT settings. Using a specified existing RCT (the ‘reference trial’) offers an opportunity to add further validity to inferences. This goal is achieved by basing the target trial design on the reference trial and benchmarking findings from the emulated study against the reference trial results. This approach adds confidence to the results obtained from the observational study before extending analysis to trial-underrepresented groups.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hernan, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758–764 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Pearce, N. & Vandenbroucke, J. P. Are target trial emulations the gold standard for observational studies? Epidemiology 34, 614–618 (2023).

    Article  PubMed  Google Scholar 

  3. Baptiste, P. J. et al. Cardiorenal effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in people underrepresented in trials: analysis of routinely collected data with emulation of a reference trial (ONTARGET). Am. J. Epidemiol. https://doi.org/10.1093/aje/kwae137 (2024).

  4. Baptiste, P. J. et al. #530 Cardiorenal effects of dual blockade with ACE inhibitors and ARBs among people with CKD: emulation of a reference trial (ONTARGET) using CPRD. Nephrol. Dial. Transplant. https://doi.org/10.1093/ndt/gfae069.562 (2024).

Download references

Author information

Authors and Affiliations

  1. Wolfson Institute of Population Health, Queen Mary University of London, London, UK

    Paris J. Baptiste

Authors
  1. Paris J. Baptiste
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paris J. Baptiste.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Baptiste, P.J. Reference-trial-informed design to explore treatment effects in trial-underrepresented subgroups. Nat Rev Nephrol (2024). https://doi.org/10.1038/s41581-024-00888-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41581-024-00888-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing